Topics:

Practice & Policy

Practice & Policy

This slide show looks at patient access to oncology agents both in the United States and abroad, and examines barriers and other constraints preventing new treatments from getting into the hands of patients.

Advocacy is about making sure that our lawmakers enact the best healthcare policies for our patients. Just as we have a duty to our patients in the clinic, we also have a duty to advocate for laws that benefit patients’ health.

A study found varying degrees of costs and benefits associated with granting early access to drugs based on PFS. In many cases, costs outstripped the benefits.

More and more cancer patients are surviving their diseases as better treatments become available, and while that’s good news, it poses challenges for clinicians.

Ahead of the World Tobacco Congress, Dr. Alan Blum and Cancer Network have partnered to assemble a four-part slideshow series addressing the history of America’s smoking pandemic. Part 1 examines the early evidence linking smoking with cancer.

The US Food and Drug Administration has approved filgrastim-sndz (Zarxio), a biosimilar of filgrastim (Neupogen), and the first such agent to be approved in the United States.

A new study suggests that cancer patients do not often request unnecessary and sometimes costly tests or treatments.

Pages

Subscribe to Practice & Policy on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.